ReviewCurrent opinion in rheumatology2013
Update in inclusion body myositis.
Review in Current opinion in rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- The health-related quality of life, mental health and mental illnesses of patients with inclusion body myositis (IBM): results of a mixed methods systematic review.Orphanet journal of rare diseases · 2022Pooled it
- Muscle Sonography in Inclusion Body Myositis: A Systematic Review and Meta-Analysis of 944 Measurements.Cells · 2022Pooled it
- Current biomarkers in inclusion body myositis.Journal of neuromuscular diseases · 2024Review
- Study to Assess Content Validity and Interrater and Intrarater Reliability of the Inclusion Body Myositis Functional Rating Scale.Neurology. Clinical practice · 2023Article
- Inclusion body myositis: from genetics to clinical trials.Journal of neurology · 2023Review
- Longitudinal Changes in MRI Muscle Morphometry and Composition in People With Inclusion Body Myositis.Neurology · 2022Observational
- Effect of intravenous immunoglobulin therapy on anti-NT5C1A antibody-positive inclusion body myositis after successful treatment of hepatitis C: A case report.eNeurologicalSci · 2019Article
- Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.Rheumatology international · 2019Article
- Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases.Croatian medical journal · 2017Article
- Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.Auto- immunity highlights · 2016Article
- Targeting protein homeostasis in sporadic inclusion body myositis.Science translational medicine · 2016Article
- BACE-1, PS-1 and sAPPβ Levels Are Increased in Plasma from Sporadic Inclusion Body Myositis Patients: Surrogate Biomarkers among Inflammatory Myopathies.Molecular medicine (Cambridge, Mass.) · 2016Article
- Targeted Molecular Therapies for SBMA.Journal of molecular neuroscience : MN · 2016Review
- The Role of the Protein Quality Control System in SBMA.Journal of molecular neuroscience : MN · 2016Review
- Treatment for inclusion body myositis.The Cochrane database of systematic reviews · 2015Review
- Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation.BMJ open · 2015Article
- Ongoing developments in sporadic inclusion body myositis.Current rheumatology reports · 2014Review
- Sporadic inclusion body myositis: new insights and potential therapy.Current opinion in neurology · 2014Article
- Inclusion body myositis.Neurologic clinics · 2014Review
- Sporadic inclusion body myositis: the genetic contributions to the pathogenesis.Orphanet journal of rare diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe purpose of this study is to review recent scientific advances relating to the natural history, cause, treatment and serum and imaging biomarkers of inclusion body myositis (IBM). RECENT
findingsSeveral theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic approaches are being investigated. New diagnostic criteria have been proposed, reflecting the knowledge that the diagnostic pathological findings may be absent in patients with clinically typical IBM. The role of MRI in IBM is expanding and knowledge about pathological biomarkers is increasing. The recent description of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially important advance that may aid early diagnosis and provides new evidence regarding the role of autoimmunity in IBM. SUMMARY: IBM remains an enigmatic and often misdiagnosed disease. The pathogenesis of the disease is still not fully understood. To date, pharmacological treatment trials have failed to show clear efficacy. Future research should continue to focus on improving understanding of the pathophysiological mechanisms of the disease and on the identification of reliable and sensitive outcome measures for clinical trials. IBM is a rare disease and international multicentre collaboration for trials is important to translate research advances into improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.